 The Food and Drug Administration granted an emergency use authorization on February 4, 2020, allowing for the use of a diagnostic panel consisting of three real-time reverse transcription PCR assays for the detection of SARS-CoV-2 infections. The panel demonstrated a high degree of correlation between results from the three assays when used to test clinical samples. Additionally, the panel had a wide dynamic range and low analytical limits of detection, making it suitable for use in a variety of settings. This article was authored by Xiaoyan Liu, Lijuan Wang, Sentil Kumar K. Saktival and others.